TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Memantine for the Treatment of Social Deficits in Youth with Disorders of Impaired Social Interactions: a Randomized-controlled Trial
Brief Summary: This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder, High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will be males and females ages 8-18.

This study consists of up to 6 visits to Massachusetts General Hospital.


Options:
A: Arm Label: D-cycloserine; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine - Extended Release (ER) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine - Extended Release (ER); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center Study of Sensory Stimulation to Improve Brain Function (Overture Study)
Brief Summary: The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment.


Options:
A: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Device: GammaSense Stimulation System (Active Settings) | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Device: GammaSense Stimulation System (Sham Settings) | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Active Settings); Assigned to Arm(s): Treatment Group | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Sham Settings); Assigned to Arm(s): Control Group
B: Arm Label: Timed Activity Intervention Protocol; Type: EXPERIMENTAL; Interventions: Behavioral: Timed Activity Intervention | Arm Label: Attention-Control Condition; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention-Control Condition | Intervention Type: BEHAVIORAL; Name: Attention-Control Condition; Assigned to Arm(s): Attention-Control Condition | Intervention Type: BEHAVIORAL; Name: Timed Activity Intervention; Assigned to Arm(s): Timed Activity Intervention Protocol
C: Arm Label: Mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirtazapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Mirtazapine; Assigned to Arm(s): Mirtazapine
D: Arm Label: SAR110894 - 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: SAR110894 - 2 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: SAR110894 - 5 mg; Type: EXPERIMENTAL; Interventions: Drug: SAR110894, Drug: Donepezil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (for SAR110894), Drug: Donepezil | Intervention Type: DRUG; Name: SAR110894; Assigned to Arm(s): SAR110894 - 0.5 mg, SAR110894 - 2 mg, SAR110894 - 5 mg | Intervention Type: DRUG; Name: placebo (for SAR110894); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Donepezil; Assigned to Arm(s): Placebo, SAR110894 - 0.5 mg, SAR110894 - 2 mg, SAR110894 - 5 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PONENTE: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients With Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy
Brief Summary: This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller medications.


Options:
A: Arm Label: Mepolizumab SC; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab, Drug: SOC | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: SOC | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC | Intervention Type: DRUG; Name: SOC; Assigned to Arm(s): Mepolizumab SC, Placebo SC
B: Arm Label: Mepolizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab, Drug: SOC | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab 100 mg | Intervention Type: DRUG; Name: SOC; Assigned to Arm(s): Mepolizumab 100 mg
C: Arm Label: Benralizumab; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab
D: Arm Label: Mepolizumab 750mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 750 | Arm Label: Mepolizumab 250mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 250 | Arm Label: Mepolizumab 75mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 75 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo saline | Intervention Type: BIOLOGICAL; Name: Mepolizumab 750; Assigned to Arm(s): Mepolizumab 750mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 250; Assigned to Arm(s): Mepolizumab 250mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 75; Assigned to Arm(s): Mepolizumab 75mg | Intervention Type: DRUG; Name: Placebo saline; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Tezacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Brief Summary: This study will evaluate the efficacy of tezacaftor in combination with ivacaftor (TEZ/IVA) in participants with cystic fibrosis (CF) aged 6 through 11 years, who are homozygous for the F508del mutation (F/F) or heterozygous for F508del with an eligible residual function mutation (F/RF).


Options:
A: Arm Label: PTC124 PO; Type: EXPERIMENTAL; Interventions: Drug: PTC124 | Intervention Type: DRUG; Name: PTC124; Assigned to Arm(s): PTC124 PO
B: Arm Label: TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA
C: Arm Label: Placebo; Type: OTHER; Interventions: Drug: Placebo | Arm Label: TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: TEZ/IVA, Drug: IVA, Drug: Placebo | Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: IVA, Drug: Placebo | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Ivacaftor, TEZ/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ivacaftor, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, TEZ/IVA
D: Arm Label: Ataluren (PTC124®); Type: EXPERIMENTAL; Interventions: Drug: Ataluren (PTC124®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren (PTC124®); Assigned to Arm(s): Ataluren (PTC124®) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Compliance and Technical Assistance for Child and Adult Care Food Program in Family Child Care Homes
Brief Summary: This study evaluates the effect of a nutrition technical assistance training program for family child care home providers on the food they serve young children in their care and the food environment in their home. Half the providers will be assigned to the nutrition program and the other half will receive a comparison on environmental health.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Other: Childhood Obesity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Childhood Obesity; Assigned to Arm(s): Treatment
B: Arm Label: Behavioral: Nutrition assistance; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition assistance | Arm Label: Behavioral: Children's environmental health; Type: EXPERIMENTAL; Interventions: Behavioral: Children's environmental health | Intervention Type: BEHAVIORAL; Name: Nutrition assistance; Assigned to Arm(s): Behavioral: Nutrition assistance | Intervention Type: BEHAVIORAL; Name: Children's environmental health; Assigned to Arm(s): Behavioral: Children's environmental health
C: Arm Label: Experimental: Phase 1 Usual Exposure; Type: EXPERIMENTAL; Interventions: Behavioral: Usual Exposure | Arm Label: Experimental: Phase 1 Mealtime support activities; Type: EXPERIMENTAL; Interventions: Behavioral: Mealtime Supports | Arm Label: Experimental: Phase 2- Usual Exposure; Type: EXPERIMENTAL; Interventions: Behavioral: Usual Exposure | Arm Label: Experimental: Phase 2- Meal Delivery and Receipt of Cookware; Type: EXPERIMENTAL; Interventions: Behavioral: Mealtime Supports | Intervention Type: BEHAVIORAL; Name: Mealtime Supports; Assigned to Arm(s): Experimental: Phase 1 Mealtime support activities, Experimental: Phase 2- Meal Delivery and Receipt of Cookware | Intervention Type: BEHAVIORAL; Name: Usual Exposure; Assigned to Arm(s): Experimental: Phase 1 Usual Exposure, Experimental: Phase 2- Usual Exposure
D: Intervention Type: BEHAVIORAL; Name: attitude change; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: adiposity prevention program; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SeRenade Parent-Child Music Class Program for Families of Children With and Without ASD
Brief Summary: This pilot study examines the impact of the SeRenade Parent-Child Music Class Program, which emphasizes parent training, peer inclusion, and musical play combined with established behavioral techniques, on the development of child social engagement, positive behavior, and parental well-being.


Options:
A: Arm Label: Music therapy/Play therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Music Therapy, Behavioral: Play therapy | Arm Label: Play therapy/Music therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Music Therapy, Behavioral: Play therapy | Intervention Type: BEHAVIORAL; Name: Music Therapy; Assigned to Arm(s): Music therapy/Play therapy, Play therapy/Music therapy | Intervention Type: BEHAVIORAL; Name: Play therapy; Assigned to Arm(s): Music therapy/Play therapy, Play therapy/Music therapy
B: Arm Label: Music therapy; Type: EXPERIMENTAL; Interventions: Other: Music therapy | Arm Label: Behavioral-based social skill training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral-based social skill training | Intervention Type: OTHER; Name: Music therapy; Assigned to Arm(s): Music therapy | Intervention Type: BEHAVIORAL; Name: Behavioral-based social skill training; Assigned to Arm(s): Behavioral-based social skill training
C: Arm Label: SeRenade Program; Type: EXPERIMENTAL; Interventions: Behavioral: SeRenade Parent-Child Music Class | Arm Label: Delayed/Waitlist Program; Type: EXPERIMENTAL; Interventions: Behavioral: Delayed Intervention | Intervention Type: BEHAVIORAL; Name: SeRenade Parent-Child Music Class; Assigned to Arm(s): SeRenade Program | Intervention Type: BEHAVIORAL; Name: Delayed Intervention; Assigned to Arm(s): Delayed/Waitlist Program
D: Arm Label: Study; Type: EXPERIMENTAL; Interventions: Behavioral: music therapy sessions . | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: music therapy sessions .; Assigned to Arm(s): Study

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telehealth Cognitive Behavioral Stress Management for Adults With Cystic Fibrosis
Brief Summary: The purpose of this study to to assess the feasibility, acceptability, and satisfaction of a telehealth cognitive behavioral stress management (CBSM) intervention among adults with cystic fibrosis (CF) who exhibit elevated anxiety and/or depression symptoms.


Options:
A: Arm Label: Growth Hormone Therapy; Type: EXPERIMENTAL; Interventions: Drug: Nutropin AQ | Intervention Type: DRUG; Name: Nutropin AQ; Assigned to Arm(s): Growth Hormone Therapy
B: Arm Label: Telehealth; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Stress Management | Arm Label: Treatment-As-Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Stress Management; Assigned to Arm(s): Telehealth
C: Arm Label: III; Type: PLACEBO_COMPARATOR; Interventions: Drug: Insulin Asparte, Drug: Repaglinide | Intervention Type: DRUG; Name: Insulin Asparte; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): III
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Repaglinide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: short-acting Insulin (Actrapid) | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: short-acting Insulin (Actrapid); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Monocentric Trial of Mechanical Bowel Preparation Alone vs Mechanical Bowel Preparation Combined With Oral Antibiotics Before Colorectal Resections for Cancer
Brief Summary: Investigation of the role of adding oral antibiotics to preoperative mechanical bowel preparation before colorectal surgery for cancer.


Options:
A: Arm Label: Bowel Preparation plus antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Other: Bowel Preparation plus antibiotics | Arm Label: Bowel Preparation; Type: OTHER; Interventions: Other: Bowel Preparation | Intervention Type: OTHER; Name: Bowel Preparation plus antibiotics; Assigned to Arm(s): Bowel Preparation plus antibiotics | Intervention Type: OTHER; Name: Bowel Preparation; Assigned to Arm(s): Bowel Preparation
B: Arm Label: Oral + Parenteral prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: Oral antibiotic drugs, Drug: Parenteral prophylaxis | Arm Label: Only parenteral prophylaxis; Type: SHAM_COMPARATOR; Interventions: Drug: Parenteral prophylaxis | Intervention Type: DRUG; Name: Oral antibiotic drugs; Assigned to Arm(s): Oral + Parenteral prophylaxis | Intervention Type: DRUG; Name: Parenteral prophylaxis; Assigned to Arm(s): Only parenteral prophylaxis, Oral + Parenteral prophylaxis
C: Arm Label: Arm I (mechanical bowel prep, oral antibiotics); Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene Glycol, Drug: Neomycin, Drug: Metronidazole Hydrochloride, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm II (oral antibiotics); Type: EXPERIMENTAL; Interventions: Drug: Neomycin, Drug: Metronidazole Hydrochloride, Procedure: Therapeutic Conventional Surgery | Intervention Type: DRUG; Name: Polyethylene Glycol; Assigned to Arm(s): Arm I (mechanical bowel prep, oral antibiotics) | Intervention Type: DRUG; Name: Neomycin; Assigned to Arm(s): Arm I (mechanical bowel prep, oral antibiotics), Arm II (oral antibiotics) | Intervention Type: DRUG; Name: Metronidazole Hydrochloride; Assigned to Arm(s): Arm I (mechanical bowel prep, oral antibiotics), Arm II (oral antibiotics) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm I (mechanical bowel prep, oral antibiotics), Arm II (oral antibiotics)
D: Intervention Type: DRUG; Name: polyethylene glycol bowel lavage solution; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
Brief Summary: A Therapeutic Exploratory Clinical Study to evaluate the efficacy and safety of DA-8010 in Patients with Overactive Bladder and to determine the optimal dose of DA-8010


Options:
A: Arm Label: Fesoterodine 8mg; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine 8mg | Arm Label: Fesoterodine 4mg; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine 4mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fesoterodine 8mg; Assigned to Arm(s): Fesoterodine 8mg | Intervention Type: DRUG; Name: Fesoterodine 4mg; Assigned to Arm(s): Fesoterodine 4mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: YM178 group; Type: EXPERIMENTAL; Interventions: Drug: YM178 | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tolterodine ER group; Type: EXPERIMENTAL; Interventions: Drug: tolterodine ER | Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): YM178 group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group | Intervention Type: DRUG; Name: tolterodine ER; Assigned to Arm(s): tolterodine ER group
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: DA-8010 Placebo, Drug: Solifenacin succinate placebo | Arm Label: DA-8010 2.5mg; Type: EXPERIMENTAL; Interventions: Drug: DA-8010 2.5mg, Drug: Solifenacin succinate placebo | Arm Label: DA-8010 5mg; Type: EXPERIMENTAL; Interventions: Drug: DA-8010 5mg, Drug: Solifenacin succinate placebo | Arm Label: Solifenacin 5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: DA-8010 Placebo, Drug: Solifenacin 5mg | Intervention Type: DRUG; Name: DA-8010 Placebo; Assigned to Arm(s): Placebo, Solifenacin 5mg | Intervention Type: DRUG; Name: DA-8010 2.5mg; Assigned to Arm(s): DA-8010 2.5mg | Intervention Type: DRUG; Name: DA-8010 5mg; Assigned to Arm(s): DA-8010 5mg | Intervention Type: DRUG; Name: Solifenacin 5mg; Assigned to Arm(s): Solifenacin 5mg | Intervention Type: DRUG; Name: Solifenacin succinate placebo; Assigned to Arm(s): DA-8010 2.5mg, DA-8010 5mg, Placebo
D: Arm Label: Fesoterodine; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine 8 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fesoterodine 8 mg; Assigned to Arm(s): Fesoterodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Robot-assisted Locomotor and Stair Climbing Training for Improving Mobility and Participation in Daily Activities in Persons Affected by Stroke: a Multicenter Randomized Controlled Clinical Trial
Brief Summary: Stair climbing up and down is an essential part of everyday's mobility. Physiotherapy is focused on muscle strengthening, real floor walking and stairs climbing tasks, but these methods do not stress in terms of intensity stair-climbing practice. The aims of this study is to compare whether an intensive robot-assisted stair climbing training (RASCT) is more effective than conventional physiotherapy (CP) for improving stair climbing ability, gait and postural control in stroke patients.


Options:
A: Arm Label: Exoskeleton Program; Type: EXPERIMENTAL; Interventions: Device: Exoskeleton Program | Arm Label: Usual Care Program; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care Program | Intervention Type: DEVICE; Name: Exoskeleton Program; Assigned to Arm(s): Exoskeleton Program | Intervention Type: OTHER; Name: Usual Care Program; Assigned to Arm(s): Usual Care Program
B: Arm Label: Samsung Hip Assist v1; Type: EXPERIMENTAL; Interventions: Device: gait rehabilitation with Samsung Hip Assist v1 | Arm Label: Conventional gait training; Type: ACTIVE_COMPARATOR; Interventions: Other: gait rehabilitation without Samsung Hip Assist v1 | Intervention Type: DEVICE; Name: gait rehabilitation with Samsung Hip Assist v1; Assigned to Arm(s): Samsung Hip Assist v1 | Intervention Type: OTHER; Name: gait rehabilitation without Samsung Hip Assist v1; Assigned to Arm(s): Conventional gait training
C: Arm Label: Robot-Assisted Stair Climbing Training; Type: EXPERIMENTAL; Interventions: Device: G-EO System | Arm Label: Conventional Physiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Physiotherapy | Intervention Type: DEVICE; Name: G-EO System; Assigned to Arm(s): Robot-Assisted Stair Climbing Training | Intervention Type: OTHER; Name: Conventional Physiotherapy; Assigned to Arm(s): Conventional Physiotherapy
D: Arm Label: Robot, then conventional training; Type: EXPERIMENTAL; Interventions: Other: Robot, then conventional training | Arm Label: Conventional, then robot training; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional, then robot training | Intervention Type: OTHER; Name: Robot, then conventional training; Assigned to Arm(s): Robot, then conventional training | Intervention Type: OTHER; Name: Conventional, then robot training; Assigned to Arm(s): Conventional, then robot training

Answer: C